Trilo Therapeutics is focused on the discovery of novel inhibitors of protein-protein interactions for therapeutic purposes.

Our Trilomer® platform of peptidomimetic binders allows for the targeted inhibition of disease-causing proteins, for the treatment of cancer, autoimmune diseases, infectious diseases, and others. In a revolution of therapeutic approaches, Trilomer® peptidomimetic binders combine the cell permeability and degradation resistance of small molecules with the large surface area of antibodies, allowing them to target both intracellular and extracellular targets. Due to their fully synthetic modular building blocks, affinity optimization and structure-activity relationships (SAR) can be performed much more rapidly than either traditional medicinal chemistry or targeted mutagenesis of biologics.


Our Degradomer® class of targeted protein degraders expands on the Trilomer® concept, allowing highly specific degradation of disease-causing proteins, including so-called “undruggable” targets like K-Ras, β-catenin, FoxP3, CBLB, and BIRC5/survivin.


Trilomer® and Degradomer® are registered trademarks of Trilo Therapeutics, Inc.



© 2020  Trilo Therapeutics, Inc.